Survival prediction for pancreatic cancer patients receiving gemcitabine treatment

Molecular and Cellular Proteomics

Volumn 9, Issue 4, 2010, Pages 695-704

  Matsubara, Junichi ^a,f   Ono, Masaya ^a   Honda, Kazufumi ^a   Negishi, Ayako ^a   Ueno, Hideki ^b   Okusaka, Takuji ^b   Furuse, Junji ^e   Furuta, Koh ^b   Sugiyama, Emiko ^c   Saito, Yoshiro ^c   Kaniwa, Nahoko ^c   Sawada, Junichi ^c   Shoji, Ayako ^d   Sakuma, Tomohiro ^d   Chiba, Tsutomu ^f   Saijo, Nagahiro ^e   Hirohashi, Setsuo ^a   Yamada, Tesshi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d Mitsui Knowledge Industry Co   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; GEMCITABINE; PROTEOME;

ACCURACY; ADULT; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALIBRATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HUMAN; LOG RANK TEST; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN MICROARRAY; SCORING SYSTEM; VALIDATION STUDY;

AGED; ANTINEOPLASTIC AGENTS; CALIBRATION; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77950663765     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M900234-MCP200     Document Type: Article

References (37)

1. Honda, K., Hayashida, Y., Umaki, T., Okusaka, T., Kosuge, T., Kikuchi, S., Endo, M., Tsuchida, A., Aoki, T., Itoi, T., Moriyasu, F., Hirohashi, S., and Yamada, T. (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 65, 10613-10622 (Pubitemid 41743757)
2. American Cancer Society (2007) Cancer Facts and Figures 2007, pp. 16-17, American Cancer Society, Atlanta, GA
3. Ministry of Health, Labour and Welfare (2009) Japanese Government: Vital Statistics of Japan, Ministry of Health, Labour and Welfare, Tokyo
4. Rosewicz, S., and Wiedenmann, B. (1997) Pancreatic carcinoma. Lancet 349, 485-489
5. Nieto, J., Grossbard, M. L., and Kozuch, P. (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13, 562-576 (Pubitemid 351872873)
6. National Comprehensive Cancer Network (2009) Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, Vol.1, National Comprehensive Cancer Network, Fort Washington, PA
7. Burris, H. A., 3rd, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F. A., Stephens, C. D., and Von Hoff, D. D. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413
8. Matsubara, J., Ono, M., Negishi, A., Ueno, H., Okusaka, T., Furuse, J., Furuta, K., Sugiyama, E., Saito, Y., Kaniwa, N., Sawada, J., Honda, K., Sakuma, T., Chiba, T., Saijo, N., Hirohashi, S., and Yamada, T. (2009) Identification of a predictive biomarker for hematologic toxicities of gemcitabine. J. Clin. Oncol. 27, 2261-2268
9. Stocken, D. D., Hassan, A. B., Altman, D. G., Billingham, L. J., Bramhall, S. R., Johnson, P. J., and Freemantle, N. (2008) Modelling prognostic factors in advanced pancreatic cancer. Br. J. Cancer 99, 883-893
10. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André , T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., Faroux, R., Lepere, C., and de Gramont, A. (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J. Clin. Oncol. 23, 3509-3516 (Pubitemid 46243495)
11. Storniolo, A. M., Enas, N. H., Brown, C. A., Voi, M., Rothenberg, M. L., and Schilsky, R. (1999) An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85, 1261-1268 (Pubitemid 29125078)
12. Hanash, S. (2003) Disease proteomics. Nature 422, 226-232
13. Yamaguchi, U., Nakayama, R., Honda, K., Ichikawa, H., Hasegawa, T., Shitashige, M., Ono, M., Shoji, A., Sakuma, T., Kuwabara, H., Shimada, Y., Sasako, M., Shimoda, T., Kawai, A., Hirohashi, S., and Yamada, T. (2008) Distinct gene expression-defined classes of gastrointestinal stromal tumor. J. Clin. Oncol. 26, 4100-4108
14. Hayashida, Y., Honda, K., Osaka, Y., Hara, T., Umaki, T., Tsuchida, A., Aoki, T., Hirohashi, S., and Yamada, T. (2005) Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin. Cancer Res. 11, 8042-8047 (Pubitemid 41698746)
15. Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P. P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S. W., Caprioli, R., Duncan, M. W., Hirsch, F. R., Bunn, P. A., Jr., and Carbone, D. P. (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort crossinstitutional study. J. Natl. Cancer Inst. 99, 838-846
16. Ono, M., Shitashige, M., Honda, K., Isobe, T., Kuwabara, H., Matsuzuki, H., Hirohashi, S., and Yamada, T. (2006) Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol. Cell. Proteomics 5, 1338-1347 (Pubitemid 44103403)
17. Negishi, A., Ono, M., Handa, Y., Kato, H., Yamashita, K., Honda, K., Shitashige, M., Satow, R., Sakuma, T., Kuwabara, H., Omura, K., Hirohashi, S., and Yamada, T. (2009) Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 100, 514-519
18. Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jr., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., and Miller, L. L. (2004) Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. 22, 3776-3783 (Pubitemid 41095218)
19. Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J. L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., and Moore, M. J. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237
20. Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., Vehling-Kaiser, U., Fuchs, M., Fleckenstein, D., Gesierich, W., Uthgenannt, D., Einsele, H., Holstege, A., Hinke, A., Schalhorn, A., and Wilkowski, R. (2006) Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946-3952 (Pubitemid 46630743)
21. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., and Parulekar, W. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (Pubitemid 46972777)
22. Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., Köhne, C. H., Mingrone, W., Stemmer, S. M., Tàmas, K., Kornek, G. V., Koeberle, D., Cina, S., Bernhard, J., Dietrich, D., and Scheithauer, W. (2007) Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25, 2212-2217
23. Japan Pancreas Society (ed) (2002) General Rules for the Study of Pancreatic Cancer, 5th Ed., Kanehara, Tokyo
24. Sugiyama, E., Kaniwa, N., Kim, S. R., Kikura-Hanajiri, R., Hasegawa, R., Maekawa, K., Saito, Y., Ozawa, S., Sawada, J., Kamatani, N., Furuse, J., Ishii, H., Yoshida, T., Ueno, H., Okusaka, T., and Saijo, N. (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J. Clin. Oncol. 25, 32-42 (Pubitemid 350003048)
25. Honda, K., Yamada, T., Hayashida, Y., Idogawa, M., Sato, S., Hasegawa, F., Ino, Y., Ono, M., and Hirohashi, S. (2005) Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 128, 51-62 (Pubitemid 40039958)
26. Idogawa, M., Yamada, T., Honda, K., Sato, S., Imai, K., and Hirohashi, S. (2005) Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology 128, 1919-1936 (Pubitemid 40824703)
27. Hothorn, T., and Zeileis, A. (2008) Generalized maximally selected statistics. Biometrics 64, 1263-1269
28. Wang, S. J., Fuller, C. D., Kim, J. S., Sittig, D. F., Thomas, C. R., Jr., and Ravdin, P. M. (2008) Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J. Clin. Oncol. 26, 2112-2117
29. Storey, J. D., and Tibshirani, R. (2003) Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U.S.A. 100, 9440-9445
30. Huang, L., Harvie, G., Feitelson, J. S., Gramatikoff, K., Herold, D. A., Allen, D. L., Amunngama, R., Hagler, R. A., Pisano, M. R., Zhang, W. W., and Fang, X. (2005) Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomics 5, 3314-3328 (Pubitemid 41192038)
31. Grote, T., Siwak, D. R., Fritsche, H. A., Joy, C., Mills, G. B., Simeone, D., Whitcomb, D. C., and Logsdon, C. D. (2008) Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8, 3051-3060
32. Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003) Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267-275 (Pubitemid 37328862)
33. Trichopoulos, D., Tzonou, A., Kalapothaki, V., Sparos, L., Kremastinou, T., and Skoutari, M. (1990) Alpha 1-antitrypsin and survival in pancreatic cancer. Int. J. Cancer 45, 685-686 (Pubitemid 20146129)
34. Lomas, D. A., and Mahadeva, R. (2002) Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy. J. Clin. Investig. 110, 1585-1590
35. Stoller, J. K., and Aboussouan, L. S. (2005) Alpha1-antitrypsin deficiency. Lancet 365, 2225-2236
36. Beatty, K., Bieth, J., and Travis, J. (1980) Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J. Biol. Chem. 255, 3931-3934
37. Rabassa, A. A., Schwartz, M. R., and Ertan, A. (1995) Alpha 1-antitrypsin deficiency and chronic pancreatitis. Dig. Dis. Sci. 40, 1997-2001